Here we show that CCT blocks the in vitro fibrillation and toxicity of α-syn A53T, a mutant responsible for Parkinson’s disease, and provides biochemical and structural insight into a specific mechanism. This evidence concerns the gene FLVCR2 and Parkinson disease.